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Available online xxxxIntroduction: In early-stage HER2 positive breast cancer (BC) patients, tumor response to neoadjuvant chemotherapy
(NACT) predict survival outcomes. Patients achieving less than pathological complete response (pCR) have a worse
prognosis, however, this group is heterogeneous. Nowadays limited data on predictive/prognostic biomarkers in pa-
tients with residual cancer disease are available.
Methods: Using next-generation sequencing technology, we evaluated a panel of 21 cancer genes in a group of HER2
positive BC patients with residual disease after NACT. A control group of patients who achieved the pCR was selected
too. The BC mutational profile was analyzed on both the tumor diagnostic biopsy and matched residual disease.
Results:Overall, the detection rate of mutations was 79% in the No-pCR group versus 90% in the pCR cohort and 98%
in the residual BC. The most mutated genes were TP53 and PIK3CA. No correlations between single gene mutations
and survival outcomes were found. In no-pCR cohort, 52% of patients had different mutational profile after NACT,
69% of them had an increased in the number of mutated genes. Mutational profile changes from diagnostic biopsy
to residual BC were a negative prognostic factor in term of relapse free survival: recurrence probability in different
gene profile sub-group was 42% vs 0% in the same profile one (P= .019).
Conclusions: Treatment selective pressure on tumor cells due to NACT changed the gene mutational profile in more than
half of BCpatientwith residual tumor disease. Treatment-induced genemutations significantly increase the risk of relapse.
Profiling primary and residual BC is a major step in order to further personalized adjuvant treatment strategy.
© 2020 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Neoadjuvant chemotherapy (NACT) is the preferred treatment option
in patients with early-stage HER2 positive breast cancer (BC). In that set-
ting the addition of trastuzumab +/- pertuzumab to standard chemother-
apy resulted in a significantly higher activity when compared to
chemotherapy alone [1–3]. The achievement of a pathological complete re-
sponse (pCR) is a powerful surrogate of long-term outcomes [4]. Patients
achieving less than pCR have a worse prognosis; however, this group is het-
erogeneous, including patients with still good outcomes or patients with
primary resistant disease [5]. Results from Katherine trial suggested that
among patients with HER2 positive early BC whit residual invasive diseaseniversity Hospital of Modena, Via del P
i).
vier Inc. on behalf of Neoplasia Pafter neoadjuvant therapy, the risk of recurrence or death was 50% lower
with adjuvant T-DM1 than with trastuzumab alone [6].
Nowadays limited and not conclusive data on predictive/prognostic
biomarkers in patients with residual disease after NACT are available [7].
This issue in likely to acquire even more relevance in the coming years
with the need to further personalize the post-neoadjuvant approach in
early BC setting.
We have evaluated by next-generation sequencing technology, a panel
of 21 cancer related genes in a group of HER2 positive BC patients treated
with NACT. We analyzed the BC mutational profile on tissue biopsy sam-
ples according to tumor response to NACT. In patients with residual
tumor disease, gene analysis was performed on the matched surgicalozzo 71, – 41122 Modena, Italy.
ress, Inc. This is an open access article under the CC BY-NC-ND license (http://
C. Omarini et al. Translational Oncology 13 (2020) 100794specimen as well. An exploratory analysis in terms of treatment outcome
and genes status was performed too.
Material and Methods
Patient Population and Samples
Patients with diagnosis of HER2 positive early BC with residual disease
after anti-HER2NACTwere identified and screened for the study. A control
group of patients with HER2 positive disease who achieved a pCR was se-
lected too. In order to be enrolled, patients must had tissue samples taken
from both the diagnostic BC biopsy and matched surgical specimens. All
BC tissue samples were formalin-fixed and paraffin-embedded (FFPE) and
archived in the Pathology Department of Modena University Hospital.
One hundred ninety-six patients with HER2 positive early BC treated
with NACT from 2008 to 2018 in Modena Cancer Center were identified.
One hundred seventy-eight of them received an anti-HER2 agent
(trastuzumab+/- pertuzumab) as part of their neoadjuvant systemic treat-
ment. Among these women, 31 underwent to BC surgery outside Modena
University Hospital. Considering patient with known breast surgery out-
come, 111 did not achieve a pCR. Among these, 83 women had available
FFPE tissues taken from both diagnostic biopsy and surgical specimens suit-
able for biomarker analyses. In order to select the real treatment-resistant
BC, we decided to perform the gene analysis only in samples with at least
1 cm of residual invasive tumors—in fact we decided to exclude from the
present work all the cases with residual invasive tumor lower than 1 cm
in longest diameter and/or scattered pattern, in order to avoid pre-
analytical bias of genomic analysis of the samples (contouring of the cellu-
lar areas, manual microdissection, etc.) potentially able to distort the pre-
liminary results of this research. The final study population included 32
patients with residual BC after NACT (No-pCR group) and a control
group of 32 patients who achieved the pCR (pCR group) (Figure 1). Of
note, all breast biopsy samples were taken before the initiation of any sys-
temic treatment.
The studywas approved by the local ethics committee (protocol number
0024589/19). Written informed consent was obtained from each living
patient.
Gene Analysis
DNA extraction was performed in the Molecular Biology Laboratory of
Modena Pathology Department. DNA extraction was performed with
QIAamp DNAMini Kit (Qiagen) from 10-μm-thick sections of FFPE tissues.
Tumor-representative areas containing at least 20% to 50% tumor cellsFigure 1. Flowchart of the study population. NACT: neoadjuvant chem
2were selected by pathologist and isolated by manual microdissection, as
suggested from guidelines. Extracted DNA was quantified with Qubit fluo-
rometer (Life Technologies) and 10 ng from each sample were amplificated
in single-tube multiplex PCR. Mutational analysis was performed with
targeted amplification-based NGS panel ‘Oncomine Solid Tumour DNA’
(ThermoFisher Scientific). The analyzed genes were: EGFR, ALK, ERBB2,
ERBB4, FGFR1, FGFR2, FGFR3, MET, DDR2, KRAS, PIK3CA, BRAF,
AKT1, PTEN, NRAS, MAP2K1, STK11, NOTCH1, CTNNB1, SMAD4,
FBXW7, and TP53. Analysis of raw sequencing data was conducted with
Ion Reporter software. Only variants with a minimum coverage of 500X
were considered to ensure variant specify. Integrative Genomic Viewer
was used for variant visualization.
Statistical Analyses
Statistical analysis was performed using STATA 13 (Stata Statistical
Software: Release 13; StataCorp LP, College Station, TX). Baseline clinical
and tumor characteristics were compared between the two tumor-
response subgroups (No-pCR vs pCR groups) by chi-square test for categor-
ical variables (i.e. breast cancer subtypes, grading, histotype, neoadjuvant
treatment, stage, recurrence and death) and by Wilcoxon Mann-Whitney
test for continuous variables (i.e. age at diagnosis). Survival outcomes of in-
terest were OS defined as the time from the diagnosis of BC to the death/
last follow up and Relapse Free Survival (RFS) defined as the time from
the date of the diagnosis of BC to the date of the first documented recur-
rence/death. OS and RFS were addressed by the Kaplan–Meier method
and log-rank test. A P value <.05 was considered statistically significant;
hazard ratio was estimated with 95% of confidence limits.
Results
Patients’ and Samples’ Characteristics
Sixty-four patients were enrolled in the study: 32 with at least 1 cm of
residual BC disease after NACT (No-pCR group) and 32 patients with pCR
(pCR group). Tumor and patient characteristics are described in Table 1.
The groups were well balanced according to baseline clinical and tumor
characteristics. As expected, the percentage of hormone receptors positive
BCwere higher in No-pCR group than in pCR cohort (P= .002). All the en-
rolled patients received trastuzumab combined with systemic chemother-
apy, in six cases with addition of pertuzumab too. The median follow up
was 45months in both groups. Considering survival outcomes, two patients
in the pCR group relapsed and are still alive while eight recurrence and four
deaths were observed in the No-pCR cohort.otherapy; BC: breast cancer; pCR: pathological complete response.
Table 1
Tumor and patient characteristics
No-pCR pCR P value
32 32
Characteristic N % N %
Age (range) 50 (28-70) 50 (26-80)
Clinical stage
II 24 (75) 23 (72) 1
III 8 (25) 9 (28)
BC subtypes
HER2+ and HR+ 20 (63) 7 (22) 0.002
HER2+ and HR- 12 (24) 25 (78)
Histotype
ductal 29 (93) 32 (100) 0.238
lobular 3 (7) 0
Grading
2 4 (10) 2 (6) 0.671
3 28 (90) 30 (94)
Neoadj pertuzumab
Yes 3 (7) 3 (7) 1
No 29 (93) 29 (93)
Neoadj chemotherapy
Taxane 5 (6) 4 (10) 1
Anthracycline + Taxane 27 (84) 28 (90)
Recurrence
Yes 8 (25) 2 (6) 0.081
No 24 (75) 30 (94)
Death
Yes 4 (10) 0 0.113
No 28 (90) 32 (100)
C. Omarini et al. Translational Oncology 13 (2020) 100794Among the 64 enrolled patients, 28 with residual BC disease and 30
with pCR had successfully gene analysis extraction performed on the diag-
nostic biopsy. Considering the No-pCR group, in 25 cases the gene analysis
was successfully performed in both biopsy and residual BC tissue, the other
seven resulting not suitable for DNA extraction procedures.
Overall, the detected mutations were 113: 37 in the pCR group, 35 in
theNo-pCRgroup and 41 in the residual BC samples (Table 2). ThemajorityTable 2
Number and type of detected mutations in the breast cancer biopsy and residual
disease
Breast cancer biopsy Residual BC tissue
pCR (N= 30) No–pCR (N=28) (N=25)
Mutations N. detected mutated genes
Number 37 35 41
Type
TP53 20 (54%) 12 (34%) 13 (32%)
PIK3CA 8 (21%) 8 (23%) 8 (19%)
MET 1 (3%) 2 (6%) 3 (6%)
KRAS 0 2 (6%) 1 (3%)
SMAD4 0 2 (6%) 1 (3%)
NOTCH1 0 1 (3%) 2 (5%)
FGFR3 1 (3%) 2 (6%) 4 (9%)
ERBB2/4 2 (5%) 1 (3%) 2 (5%)
PTEN 0 1 (3%) 3 (6%)
DDR2 2 (5%) 1 (3%) 1 (3%)
ALK 1 (3%) 0 1 (3%)
BRAF 1 (3%) 0 0
STK11 1 (3%) 1 (3%) 0
NRAS 0 1 (3%) 0
EGFR 0 1 (3%) 1 (3%)
AKT1 0 0 1 (3%)
3of the mutations (77%) were single nucleotide variation (SNV) while in the
other cases were insertion or deletion (INDEL).Primary Tumor Mutation (No-pCR Group vs pCR Group)
Overall, 72 mutations were found in the diagnostic BC biopsies. Thirty-
seven of them were in the pCR group and 35 in residual disease cohort
(Table 2). Considering the mutational burden, in No-pCR cohort six pa-
tients had no detected mutation (21%), 9 one detected mutation (32%),
12 two detected mutations (43%) and 1 three detected mutations (4%)
(Table 3). In the pCR group, we found three patients with no mutation
(10%), 18 with one mutation (60%), 8 with two mutations (27%) and 1
with three mutations (3%) (Table 3). Regarding the meaning of the de-
tected mutations, in both groups, 15 mutations were known to be patho-
genic/likely pathogenic ones (PI3KCA, TP53, SMAD4, DDR2, PTEN)
(Table 2). Moreover, a MET mutation with uncertain significance was
found in the pCR cohort. Considering the detected genes, in both cohorts,
TP53 and PIK3CA were the most mutated ones. In particular, mutations
of TP53 and PIK3CA were detected in 67% and 27% of pCR women versus
43% and 28% of No-pCR patients, respectively (P value not significant).
In the pCR cohort, both ERBB2/ERBB4 and DDR2 were mutated in 5%
of cases; all the other mutated genes were detected in the 3% of women.
Considering the No-pCR group, SMAD4 and FGFR3 were detected in 6%
of cases followed by KRAS and MET in 5% of cases. Of note, no difference
in the rate of PIK3CA mutation according to hormone receptors status
was found (22% HR positive and 27% of HR negative). As expected,
TP53 mutation was higher in HR negative BC compared to HR positive
ones (59% vs 37%).Comparison Between Primary Tumor and Residual Disease
In the No-pCR group, twenty-five women had DNA analysis performed
on both diagnostic tumor biopsy and matched residual BC. Seven out of 32
cases were not suitable for DNA extraction procedures. Overall, 41 muta-
tions were found (Table 3). The total number of the detected mutations
has increased from the biopsy to the matched surgical specimen (32 vs 41
respectively) (Figure 2). Among those cancers that changed their muta-
tional profile from breast biopsy to residual disease after NACT, in 69% of
cases there was an increase in the absolute number of mutations. In partic-
ular, in nine cases the number ofmutated genes increased in the surgical tis-
sue while in two cases the primary mutations were lost. In two cases the
mutation profile of residual BC was completely different from the primary
biopsy one. Considering the mutational burden in the residual tumors,
only two patients had no mutation detected, 10 had one mutation, nine
had twomutations, three had threemutations and 1 BC presented four mu-
tations (Table 3). Regarding themeaning of the detectedmutations, 14mu-
tations found in the surgery tissues were known to be pathogenic/likely
pathogenic (PI3KCA, TP53). Comparing the detected mutated genes in
breast biopsy and matched surgical sample, we found an increase number
of PIK3CA, TP53, MET, NOTCH1, FGFR3, and PTENmutations in the resid-
ual BC tissue (Figure 3).Table 3
Patients’mutational burden in the three groups: pCR, No-pCR and residual disease
pCR No-pCR Residual disease
N. of patients (%) N. of patients (%) N. of patients (%)
No mutation 3 (10%) 6 (21%) 2 (8%)
1 mutation 18 (60%) 9 (32%) 10 (40%)
2 mutations 8 (27%) 12 (43%) 9 (36%)
3 mutations 1 (3%) 1 (4%) 3 (12%)
4 mutations 0 0 1 (4%)
Figure 2. Different mutational profile among diagnostic breast cancer biopsy and matched residual breast cancer.
C. Omarini et al. Translational Oncology 13 (2020) 100794Prognostic Value of Detected Gene Mutations
As expected patients who achieved a pCR had significantly lower risk of
relapse compared to patients with residual disease (RFS: 25% vs 6%, re-
spectively; P= .037). No statistically significant differences in RFS accord-
ing to the detected mutational burden of disease have been found. In
particular, therewere no differences between patientswith no detectedmu-
tations and patients with at least one gene mutation (33% versus 10%, re-
spectively, P = .119) as well as between patients with no or one
mutation and those with two or more mutations (11% versus 18%, respec-
tively, P= .35). The detection of TP53 or PIK3CAmutations did not signif-
icantly influence the risk of relapse too (P= .68).
On the contrary, changes in the gene mutational profile during the
NACT treatment significantly influenced the risk of relapse. In particular,
patients with different mutational profile between diagnostic biopsy and
matched residual BC had a significantly higher risk of recurrence compared
to patients with no treatment induced genemodifications. In fact, all the re-
currences occurred in the subgroup of patients with different gene status
after NACT, independently from pCR groups. Forty-two per cent of patients
with treatment induced gene changes relapsed (P = .019, log-rank test)0
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Figure 3. Biopsy versus surgery ti
4(Figure 4A). In particular, the increase of the mutational tumor burden
seemed to be mostly involved in the risk of relapse (Figure 4B).
Survival analysis in term of overall survival was not performed because
of the few number of accorded deaths at the time of the analysis. All the
deaths were in the subgroup of No-pCR patients.
Discussion
BC is a dynamic and heterogeneous disease. New gene analysis technol-
ogy showed that there are several BCs with different genomic profiles
reflecting in different treatment sensitivity and survival outcomes [8].
Moreover, during cancer progression tumors acquired genomic mutations
able to influence treatment sensitivity too [9]. The heterogeneity of the tu-
mors, exacerbated by the selective pressures imposed by the systemic treat-
ments, confers a major resistance to anti-cancer drugs [9]. In this context,
emerging evidence from NACT trials showed how the residual tumor ge-
netic landscape is largely involved in anticancer sensitivity/resistance
mechanisms [10]. Proper understanding of residual disease mutational
landscape may lead to a personalized systemic adjuvant treatment ap-
proach. Against this backdrop, we evaluated a panel of 21 genes involvedidual disease
ssue detected mutated genes.
Figure 4. (A) Kaplan-Meier curves for Relapse Free Survival according to
modification in breast cancer mutational profile pre- versus post-NACT. (B)
Kaplan-Meier curves for relapse free survival for subgroup of patients with
acquired gene mutations versus lost gene mutations, (P value, log-rank test)
C. Omarini et al. Translational Oncology 13 (2020) 100794in treatment resistance, comparing cancer samples taken from the diagnos-
tic biopsy and the residual tumor after NACT selected on the basis of treat-
ment sensitivity (No-pCR versus pCR group). Considering results from the
BC diagnostic biopsy analysis, the detection rate of mutations was 79% in
No-pCR group versus 90% in pCR one. The high rate of mutations detected
on the diagnostic biopsy underlines that the analyzed genes were highly in-
volved in the first steps of cancer progressions. The most frequently mu-
tated genes were TP53 and PIK3CA in both No-pCR and pCR groups of
patients. The mutation rate found in our study population was similar to
those reported in literature (30% for PIK3CA and 50% for TP53) [11,12].
TP53 mutations were overall present in 55% of the biopsy, mainly in
pCR subgroup (67% vs 43%). This finding confirms a higher rate of pCR
in TP53 mutated patients according to other published researches [13].
Even if the TP53 status seems to be a predictor for pCR, survival studies
showed worse outcomes in TP53-mutated patients [13]. This evidence
may depend by the fact that TP53 induces arrest and senescence instead
of apoptosis [14]. Several pre-clinical evidence have shown that senescent
cells drive relapse by producing cytokines that promote proliferation, sur-
vival, angiogenesis and increase in cancer stem cells population [15]. In
our analysis, no correlation between TP53 status and risk of relapse/5death has been found likely due to the high rate of TP53 mutated tumors
and the low rate of relapse in the study population.
PIK3CA mutations were present in 27% of patients, similar between
pCR and No-pCR subgroup (27% vs 28%). Preclinical evidence suggests
that PIK3CA mutated cancer cells have an abnormal pathway activation,
which lead to resistance to trastuzumab [16]. A meta-analysis on the role
of PIK3CA mutations and response to NACT published in 2018 confirmed
these results [11]. The predictive value of PIK3CA mutation is less clear
in patients selected according to hormone receptors status. Higher pCR
rate was found in PIK3CA mutated-HER2 positive-hormone receptors posi-
tive BC but not in hormone receptors negative ones [11]. Looking at our
pCR subgroup, only seven women had hormone receptors positive BC.
This may justify the lack of significant correlation between the PIK3CAmu-
tation and the pCR rate in our study population.
Overall, the lack in the identification of a prognostic and/or predictive
mutational gene profile may be justified by the complexity of the BC biol-
ogy. Knowledge on cancer progression suggested that the carcinogenesis
is moved by multiple gene mutations that generate changes in several mo-
lecular pathways involved in cell survival [17]. Abnormalities in DNA
methylation, microRNA and protein expression increased the molecular ar-
chitecture of BC too [17].
Considering residual BC disease, it is well clear that NACT is able to
change the tumor mutational profile. Since the presence of residual tumor
after NACT confers an increased risk of recurrence, a better characterization
of these patients is necessary [18]. Our findings showed a potential prog-
nostic value of treatment induced mutational burden modifications.
Changes in the residual BC mutational landscape (acquired or lost muta-
tions) were negative prognostic factors in term of RFS. In particular, pa-
tients with a different mutational profile between diagnostic biopsy and
residual disease had a significantly higher risk of relapse compared to
those without gene modifications.
Despite preliminary and to be confirmed in prospective clinical trials,
these results may help in the selection of those patients with residual
HER2 positive disease after NACT, and therefore candidates for post-
NACT treatments—on the model of the KATHERINE study—for further
prolong DSF and OS.
Overall, the total number of detected mutations was increased from the
matched BC biopsy to the surgical specimen (32 vs 41 respectively) as well
as the number of patients with at least one detected mutations (76% vs
92%). More than half of the patients changed the mutational profile during
the neoadjuvant treatment, 69% increased the number of the detected mu-
tated genes in the surgical tissue compared to the matched biopsy. In two
cases the mutational profile of residual tumor was completed different
from the primary biopsy one. Both these patients early relapsed. In particu-
lar, even if not statistically significant, the acquisition of new mutations
compared to their loss seems to increase the risk of relapse too. All the re-
currence occurred in the subgroup of patients with an increased mutational
burden from the biopsy to the residual disease. The selective pressure of the
NACT on tumor cells can explain these data. In resistant cancer cells, ther-
apy could induce genemutations able to confer amore aggressive tumor be-
havior, reflecting in worse survival outcomes. Our results are useful in the
present context, when NACT is more and more used to select the best
post-operative treatment. Based on the detection of different mutational
profile from biopsy to surgery, patients could be selected for different adju-
vant treatment strategy. In particular, women with changes in mutational
profile could be better candidate for an alternative adjuvant treatment
(such as TDM1) [6], whereas patients maintaining the same molecular pro-
file could stay on the same treatment used before surgery (such as
trastuzumab).
In spite of our findings, this study presents two main limitations and
must be considered hypothesis generating. Firstly, this is a retrospective
study with a small sample size. Secondary, due to the retrospective na-
ture of our analysis, samples were fixed and processed for storage in dif-
ferent periods and by different technicians, with no purpose of genomic
analysis. This variability might have reduced the quality and preserva-
tion of some tissues.
C. Omarini et al. Translational Oncology 13 (2020) 100794Conclusion
Survival benefit in early BC patients is strictly linkable to the improve-
ment in genomic BC profile knowledge. Findings from our research confirm
that mutations on driver genes are present from the first steps of BC carci-
nogenesis and/or may arise during cancer treatment. In particular, during
NACT BC may acquire gene mutations able to confer resistance to anti-
cancer systemic therapy itself. The selective pressures imposed by chemo-
and targeted-therapies changes the mutational BC landscape in the major-
ity of patients with residual tumor disease. Our results demonstrated that
patients with changes in the gene status, as both gains and losses of muta-
tions, have an increased risk of relapse. The identification of those patients
could be useful in themanagement of adjuvant treatment strategy. Profiling
BC sample before and after any interventions is the first critical step in the
precision medicine era.
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